NCT00002205View on ClinicalTrials.gov

An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen

NACompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Abacavir sulfate

DRUG

Amprenavir

Trial Locations (1)

277093398

Glaxo Wellcome Inc, Research Triangle Park

Sponsors

Lead Sponsor

Glaxo Wellcome
All Listed Sponsors
lead

Glaxo Wellcome

INDUSTRY

NCT00002205 - An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen | Biotech Hunter | Biotech Hunter